Advertisement

Related Videos

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Welcome and Introduction to Vi3C

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Peter Clark, MA, MD, FRCP: A Payer Perspective

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Advertisement

Advertisement




Nov
05
Today In Oncology
Extended ERSPC Analysis Demonstrates Long-Term Mortality Benefit of PSA Screening for Prostate Cancer
RCC: Lenvatinib/Everolimus Extends PFS After PD-1 Inhibition
Final Overall Survival Confirms Benefit of Durvalumab Plus FLOT in Resectable Gastric and Gastroesophageal Junction Adenocarcinomas
Lung Cancer Advancements Are Saving More Lives Than Ever but Funding Cuts May Hinder Progress
Extensive LA-Area Fires Altered Blood Proteins in Firefighters
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo